Non-Small-Cell Lung Cancer
151
16
22
61
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
26 trials with published results (17%)
Research Maturity
61 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
13.9%
21 terminated out of 151 trials
74.4%
-12.2% vs benchmark
16%
24 trials in Phase 3/4
43%
26 of 61 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 61 completed trials
Clinical Trials (151)
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations
Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With Osimertinib
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
The Research Plan of Taiwan Precision Medicine
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
Lorlatinib Continuation Study
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors